Medpace Complaint Overview
The Medpace class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Medpace common stock. The class action is pending in the U.S. District Court for the Southern District of Ohio. It is captioned Durbin v. Medpace Holdings Inc., et al., No. 1:26-cv-00346.
If you lost money on your Medpace investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Medpace Being Sued for Securities Fraud?
Medpace has been sued for securities fraud following a significant stock drop resulting from potential violations of the federal securities laws. The decline in Medpace’s stock price caused significant losses to investors.
Medpace is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
During the relevant period, Medpace allegedly misled investors concerning its book-to-bill ratio for 4Q 25. According to Medpace, “our award notifications were strong. Cancellations were down across the pipeline.” Medpace also discussed how cancellations were “very well behaved.”
As alleged, in truth, Medpace’s cancellations had increased causing its book-to-bill ratio to decline.
Why did Medpace’s Stock Drop?
On February 9, 2026, Medpace released its 4Q 2025 financial results, reporting that its book-to-bill ratio declined to 1.04 due to elevated cancellations.
This news caused the price of Medpace stock to drop nearly 16%, from $530.35 per share on February 9, 2026 to 446.05 per share on February 10, 2026.
BFA is also investigating recent reports that Medpace’s cancellations continued to increase and book-to-bill ratio continued to decline, reaching as low as 0.88 for 1Q 26. The company’s President, Jesse Geiger, also announced his intention to resign.
On this news, the price of the company’s stock declined roughly 23% during afternoon trading on April 23, 2026.
Medpace (MEDP) Stock Chart
Image Caption: NASDAQ online chart showing Medpace’s (MEDP) stock drop following the February 2026 and April 2026 announcements.
What is the Medpace Leadership Deadline?
You may ask the Court no later than June 8, 2026, to appoint you as Lead Plaintiff through counsel of your choice.
To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
How Do I Submit My Information?
If you lost money when Medpace securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
